| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center NCT05095948 | M.D. Anderson Cancer Center | — |
| Recruiting | Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid NCT07336238 | University of Washington | Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Not Yet Recruiting | Adoption of Audio Recording in the Outpatient Supportive Care Center NCT04871477 | M.D. Anderson Cancer Center | — |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers NCT06911008 | Mayo Clinic | Phase 1 |
| Recruiting | TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, NCT07189195 | University of California, Davis | Phase 1 |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers NCT06606990 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causin NCT06745024 | NRG Oncology | Phase 3 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or NCT06311214 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metasta NCT06630416 | Northwestern University | Phase 2 |
| Completed | A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metas NCT06644170 | University of Washington | Phase 1 |
| Recruiting | Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases NCT06328686 | Emory University | EARLY_Phase 1 |
| Recruiting | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumo NCT05638295 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors NCT05653661 | Mayo Clinic | Phase 1 |
| Recruiting | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases NCT06549478 | City of Hope Medical Center | Phase 1 |
| Recruiting | Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers NCT05691517 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid NCT05687136 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced C NCT05564468 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Meta NCT06320405 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Active Not Recruiting | Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors NCT06076135 | Chuangzhen Chen | Phase 2 |
| Recruiting | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Recepto NCT06043713 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for NCT05803382 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effective NCT05691491 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Trea NCT05554380 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation NCT05728372 | City of Hope Medical Center | EARLY_Phase 1 |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad NCT05372640 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMA NCT05554341 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alteratio NCT05687110 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer NCT05847686 | University of Washington | Phase 1 / Phase 2 |
| Recruiting | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunot NCT05039632 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tum NCT05733949 | City of Hope Medical Center | N/A |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advance NCT05327010 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcino NCT05472220 | Pamela Munster | Phase 1 |
| Active Not Recruiting | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment NCT05455606 | SWOG Cancer Research Network | N/A |
| Suspended | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers NCT05372614 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metasta NCT05503251 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic NCT05111561 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoin NCT05530759 | Mayo Clinic | — |
| Recruiting | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR NCT05371132 | City of Hope Medical Center | Phase 1 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors NCT05010096 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial NCT05222620 | Mayo Clinic | Phase 2 |
| Suspended | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors NCT04840589 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis NCT05059678 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Perception of Cure Among Patients With Metastatic Cancer NCT04820894 | City of Hope Medical Center | — |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor NCT04514497 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Recruiting | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of NCT05101356 | Tianhong Li | Phase 1 / Phase 2 |
| Active Not Recruiting | Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for P NCT04960787 | SWOG Cancer Research Network | N/A |
| Active Not Recruiting | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Express NCT04957615 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Radiosurgery Before Surgery for the Treatment of Brain Metastases NCT04895592 | Emory University | EARLY_Phase 1 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Car NCT04090619 | M.D. Anderson Cancer Center | — |
| Recruiting | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Pl NCT04585958 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supporti NCT05091632 | M.D. Anderson Cancer Center | — |
| Recruiting | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors NCT04879121 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Can NCT05058339 | M.D. Anderson Cancer Center | — |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Terminated | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Sol NCT04800627 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metasta NCT04785287 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Ad NCT04062552 | University of Rochester NCORP Research Base | N/A |
| Terminated | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTI NCT04729725 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer NCT04697524 | University of California, San Francisco | N/A |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning NCT04889144 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, NCT04693468 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors NCT04539574 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer NCT04294628 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorecta NCT04329494 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without NCT04317105 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Pati NCT04197713 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Testing the Safety of CB-5339 in Patients With Cancer NCT04372641 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | NCI COVID-19 in Cancer Patients, NCCAPS Study NCT04387656 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Me NCT04068194 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors NCT04266912 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations NCT04233567 | Sameek Roychowdhury | Phase 2 |
| Active Not Recruiting | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydroch NCT03872427 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients W NCT03842228 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Genetic Testing in Guiding Treatment for Patients With Brain Metastases NCT03994796 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients NCT04021043 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial NCT03907475 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer NCT03927885 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Withdrawn | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423 | Sameek Roychowdhury | Phase 2 |
| Completed | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies NCT03831295 | Ronald Levy | Phase 1 |
| Active Not Recruiting | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 NCT03284385 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Terminated | Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer NCT03579446 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Active Not Recruiting | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma NCT03502733 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases NCT05054998 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors NCT03525925 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Ad NCT03583255 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors NCT03030378 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors NCT03366103 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver NCT03217253 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers NCT03017833 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instabil NCT03436563 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors NCT03237390 | Mayo Clinic | Phase 1 |
| Recruiting | Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients NCT06015932 | Mayo Clinic | N/A |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or NCT03065387 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Antico NCT03080883 | Academic and Community Cancer Research United | Phase 3 |
| Active Not Recruiting | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer NCT02862275 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery NCT03184038 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Active Not Recruiting | Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue i NCT03035409 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by S NCT02503709 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-I NCT02321501 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immun NCT02710253 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lym NCT02408861 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for NCT02317874 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Recruiting | Collection and Storage of Tissue and Blood Samples From Patients With Cancer NCT02474160 | National Cancer Institute LAO | — |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurger NCT02387905 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors NCT02143401 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors NCT02079740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction NCT02070549 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus NCT01822522 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastati NCT01787500 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT01366144 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian C NCT01012817 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Remove NCT00576654 | National Cancer Institute (NCI) | Phase 1 |